Clinical trials: Specific Immunotherapy
Tuberculosis
Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine
The study is a single centre, phase I, open, randomized, by intranasal and sublingual application trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-01L tuberculosis vaccine in BCG-vaccinated…
- Trial name
- NCT03017378
- Testing
- TB/FLU-01L
- Where
- Kazakhstan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
Pollen Allergy, Venom Allergy
Identification of B Regulatory Cells by Flow Cytometry
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients…
- Trial name
- NCT06876506
- Testing
- Venepuncture, Allergen Specific Immunotherapy
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
HIV-1
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT06252402
- Testing
- CMV/HIV-CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Type I Hypersensitivity
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated.
- Trial name
- NCT00109759
- Testing
- RagweedMATAMPL
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Cervical Cancer
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being
Cervical cancer the most frequent neoplasm and the third mortality rate of malignancies of the women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide.
- Trial name
- NCT00155792
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Ovarian Cancer
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen
Ovarian cancer has the highest mortality rate of gynecologic malignancies and the overall 5-year survival rate of ovarian cancer is only 20-30%.
- Trial name
- NCT00155935
- Testing
- venous puncture
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Allergic Rhinoconjunctivitis, Healthy Volunteers
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC). There are 2 treatments in this study.
- Trial name
- NCT02297490
- Testing
- Allergovit 6-grasses
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Allergopharma GmbH & Co. KG
Ovarian Cancer
The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients
Ovarian cancer is the first in mortality rate of the gynecologic malignancies and the overall 5-year survival rate of ovarian cancer is only 20-30%. Besides, the incidence of ovarian cancer increased in recent years in Taiwan.
- Trial name
- NCT00173394
- Where
- Taiwan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Lung Cancer (Diagnosis), Pulmonary Nodule Persistent
Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant…
- Trial name
- NCT07047573
- Testing
- PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zhao Jun
Bladder Cancer
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and…
- Trial name
- NCT01198808
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Allergen Immunotherapy, Immunological Mechanisms,Monosensitized,Polysensitized,Clinical Efficacy
Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis and/or Asthma.
The incidence of allergic rhinitis and asthma is increasing in throughout the world as well as our country. Allergen-specific immunotherapy has been in use for almost 100 years.
- Trial name
- NCT01795846
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ankara University
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics